Veno-venous extracorporeal life support (V-V ECLS or V-V ECMO) has been adopted as a rescue support in severe cases of COVID-19 ARDS. Initial reports on the use of V-V ECLS in COVID-19 patients reported very high mortality rates (57-94%), but subsequent studies showed much lower rates (30-40%). The aim of this study is to analyze demographic features, clinical course and outcomes of COVID-19 treated with V-V ECLS during the Italian 'third wave', in which the alpha variant was prevalent in the country.
Benedetto, M., Piccone, G., Baiocchi, M., Cerchierini, E., Adversi, M., Rossi, A., et al. (2022). Increased duration and similar outcomes of V-V ECLS in patients with Covid-19 Ards compared to non-Covid ards: single center experience. ARTIFICIAL ORGANS, 1, 1-21 [10.1111/aor.14463].
Increased duration and similar outcomes of V-V ECLS in patients with Covid-19 Ards compared to non-Covid ards: single center experience
Adversi, Marco;Dell'Olio, Alessio;Ranieri, V Marco;Tonetti, Tommaso
2022
Abstract
Veno-venous extracorporeal life support (V-V ECLS or V-V ECMO) has been adopted as a rescue support in severe cases of COVID-19 ARDS. Initial reports on the use of V-V ECLS in COVID-19 patients reported very high mortality rates (57-94%), but subsequent studies showed much lower rates (30-40%). The aim of this study is to analyze demographic features, clinical course and outcomes of COVID-19 treated with V-V ECLS during the Italian 'third wave', in which the alpha variant was prevalent in the country.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
